Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » NEXM

 - UBBFriend: Email this page to someone!    
Author Topic: NEXM
rdweinert
Member


Rate Member
Icon 1 posted      Profile for rdweinert     Send New Private Message       Edit/Delete Post   Reply With Quote 
http://stockcharts.com/h-sc/ui?s=NEXM&p=D&yr=0&mn=3&dy=0&id=p44425523997

bollies tightening up, MACD crossed, CCI/RSI look good. Has FDA approval pending, and rumor has it that it should be out soon...

Posts: 170 | From: Great Lakes, IL | Registered: Jan 2010  |  IP: Logged | Report this post to a Moderator
rdweinert
Member


Rate Member
Icon 1 posted      Profile for rdweinert     Send New Private Message       Edit/Delete Post   Reply With Quote 
NexMed, Inc. (Nasdaq:NEXM) is a specialty contract research organization – also called clinical research organization (CRO). It has decades’ experience of providing “in vitro and in vivo pharmacology services and research models”. Recently, it acquired Bio-Quant Inc. – a move that made it the largest CRO in the San Diego region. It is also a specialty pharmaceutical company that has a number of products under its pipeline. All these products have been developed using the company’s NexACT® drug delivery technology. Among its most popular products are an alprostadil treatment (which is currently in its second phase and is intended for sexual arousal disorders in females), another alprostadil treatment (intended for erectile dysfunction) and several other treatments for psoriasis and onychomycosis. For several months now, it is has been waiting for a response from the Food and Drug Administration (FDA). It is on the subject of the company’s carcinogenicity (CAC) assessment package. On January 8, 2010, the company disclosed that the FDA is likely to let the company know about its decisions within “the next two months”. As a result, all the stakeholders are expecting the FDA’s decision by no later than March 8, 2010.


Why are NexMed and its stakeholders eagerly waiting for the FDA decision? The answer was provided by the company itself. The decision is crucial because, without it, the company cannot proceed with its efforts to find a partner for its product Femprox®. This product aims to correct sexual dysfunction in females. And without a partner, NexMed cannot bring Femprox® into the market.


There are several well reputed global pharmaceutical companies who want to partner with NexMed for commercializing Femprox®. All of them will have to wait – at least until March 8.

Posts: 170 | From: Great Lakes, IL | Registered: Jan 2010  |  IP: Logged | Report this post to a Moderator
rdweinert
Member


Rate Member
Icon 1 posted      Profile for rdweinert     Send New Private Message       Edit/Delete Post   Reply With Quote 
http://stockcharts.com/h-sc/ui?s=NEXM&p=D&yr=0&mn=3&dy=0&id=p49655325066
Posts: 170 | From: Great Lakes, IL | Registered: Jan 2010  |  IP: Logged | Report this post to a Moderator
rdweinert
Member


Rate Member
Icon 1 posted      Profile for rdweinert     Send New Private Message       Edit/Delete Post   Reply With Quote 
FDA approval should be out any day now. Had a bit of a bearish day today, but it you played it right you are up! if news doesn't break tomorrow then wait for it to dip down, and that will give you a good entry point.

http://stockcharts.com/h-sc/ui?s=NEXM&p=D&yr=0&mn=3&dy=0&id=p00889673793

Posts: 170 | From: Great Lakes, IL | Registered: Jan 2010  |  IP: Logged | Report this post to a Moderator
rdweinert
Member


Rate Member
Icon 1 posted      Profile for rdweinert     Send New Private Message       Edit/Delete Post   Reply With Quote 
keep an eye on this one. FDA approval could be out any day now! this one is ready to pop.
Posts: 170 | From: Great Lakes, IL | Registered: Jan 2010  |  IP: Logged | Report this post to a Moderator
rdweinert
Member


Rate Member
Icon 1 posted      Profile for rdweinert     Send New Private Message       Edit/Delete Post   Reply With Quote 
http://stockcharts.com/h-sc/ui?s=NEXM&p=D&yr=0&mn=3&dy=0&id=p83311885917

PARSAR are putting it on a buy. MACD is soft buy, CCI turning up slightly, soft buy, RSI in buy zone but sideways. this company has been putting out some good PR, and has some good things going.

Posts: 170 | From: Great Lakes, IL | Registered: Jan 2010  |  IP: Logged | Report this post to a Moderator
rdweinert
Member


Rate Member
Icon 1 posted      Profile for rdweinert     Send New Private Message       Edit/Delete Post   Reply With Quote 
NexMed, Inc. (Nasdaq: NEXM) announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.

Specifically, rodents that received insulin injections incorporating the NexACT technology showed bio-equivalency to Lantus(R) in controlling glucose levels in the blood. Further studies in rodents showed that NexACT was able to deliver Taxol(R) subcutaneously in levels similar to those previously observed in NexACT-based oral Taxol formulation without any apparent toxicity. Lantus, a product of Sanofi Aventis, is a commonly prescribed insulin injection for treating diabetes.

Posts: 170 | From: Great Lakes, IL | Registered: Jan 2010  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share